NYSE:PFE

Pfizer (PFE) Stock Forecast, Price & News

$37.60

-0.23 (-0.61%)

(As of 05/26/2023 07:00 PM ET)

Compare

Today's Range: $37.56
▼
$38.44
50-Day Range: $36.48
▼
$41.79
52-Week Range: $36.17
▼
$54.93

Volume: 20.23 million shs
Average Volume: 24.02 million shs
Market Capitalization: $212.26 billion

P/E Ratio: 7.40
Dividend Yield: 4.36%
Price Target: $47.33

Pfizer MarketRank™ Forecast

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 25.9% Upside
$47.33 Price Target
Short Interest: Healthy
0.81% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.04
Upright™ Environmental Score
News Sentiment: 0.46
Based on 46 Articles This Week
Insider Trading: Acquiring Shares
$5.08 M Bought Last Quarter
Proj. Earnings Growth: -0.30%
From $3.35 to $3.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.34 out of 5 stars

Medical Sector

6th out of 1,010 stocks

Pharmaceutical Preparations Industry

2nd out of 494 stocks

4.2

Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.33, Pfizer has a forecasted upside of 25.9% from its current price of $37.60.
Amount of Analyst Coverage
Pfizer has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.81% of the outstanding shares of Pfizer have been sold short.
Short Interest Ratio / Days to Cover
Pfizer has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pfizer has recently increased by 4.67%, indicating that investor sentiment is decreasing.

5.0

Dividend Strength

Dividend Leadership
Pfizer is a leading dividend payer. It pays a dividend yield of 4.36%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pfizer has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 32.28%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 49.10% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pfizer has received a 71.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "Pneumococcal vaccines", and "Apixaban" products. See details.
Environmental Sustainability
The Environmental Impact score for Pfizer is -2.04.

2.5

News and Social Media Coverage

News Sentiment
Pfizer has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 46 news articles for Pfizer this week, compared to 24 articles on an average week.
Search Interest
Only 221 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.
MarketBeat Follows
90 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 34% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,076,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.05% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
67.62% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to decrease by -0.30% in the coming year, from $3.35 to $3.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 7.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.88.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 7.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.25.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

May 27, 2023 | marketbeat.com

MarketBeat Week in Review – 5/22 - 5/26 (PFE)

The debt ceiling standoff and inflation continue to fight for investors’ attention as we head into what is historically a quieter period for the markets

May 25, 2023 | marketbeat.com

Pfizer Has the Prescription for Higher Share Prices

Pfizer's 4% yield is more attractive than ever after positive results from a study and an upgrade from Cantor Fitzgerald.

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 23, 2023 | marketbeat.com

Doximity is an Overlooked Medical Ecosystem AI Play (PFE)

Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like

May 19, 2023 | marketbeat.com

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (PFE)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

May 16, 2023 | marketbeat.com

The Turnaround for Weight Watchers is Taking Shape (PFE)

Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares

May 10, 2023 | marketbeat.com

5 Best Healthcare Sector ETFs (PFE)

What do you need to know about investing in healthcare ETFs? Learn more about both healthcare and ETFs with MarketBeat.

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

May 8, 2023 | marketbeat.com

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results (PFE)

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

May 2, 2023 | marketbeat.com

High-Yield Pfizer Falls Off The COVID Cliff, And Survives

Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.

May 2, 2023 | marketbeat.com

Pfizer tops Q1 forecasts; vaccine sales slide as expected

Pfizer topped Wall Street expectations even as sales of its top-selling COVID-19 vaccine crumbled in the first quarter

May 27, 2023 | finance.yahoo.com

Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income

May 27, 2023 | finance.yahoo.com

3 No-Brainer Stocks to Buy for Under $100 Right Now

May 27, 2023 | seekingalpha.com

Pfizer: Undervaluation In The Post-COVID-19 Era

May 26, 2023 | markets.businessinsider.com

Analysts Are Neutral on These Healthcare Stocks: Illumina (ILMN), Pfizer (PFE)

May 26, 2023 | msn.com

Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

May 26, 2023 | finance.yahoo.com

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

May 26, 2023 | finance.yahoo.com

UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract

May 26, 2023 | finance.yahoo.com

Brussels and Pfizer agree deal to cut supply of Covid vaccines